Lynn Lochner
Psychiatric/Mental Health · Kankakee, ILNPI 1801238282
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,614 of the $40,866 with a category attached, or 60.2%. 46 manufacturers reported payments, led by AbbVie at 49.6% of the total. Reporting peaked in 2023 at $18,501 and has fallen 54.3% since, to $8,456 in 2025. Among psychiatric/mental health clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 549 payments — averaging $74.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$20K
- Otsuka America Pharmaceutical, Inc.$10K
- E.r. Squibb & Sons, L.L.C.$5K
- Johnson & Johnson$678
- Novo Nordisk$448
- Nestle Healthcare Nutrition Inc.$397
- plus $4K from 40 others
What the payments were for
- Consulting fees$3,2848%
- Speaking & faculty fees$24,61460%
- Travel & lodging$2,6627%
- Food & beverage$10,24025%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,866 in reported general payments places this provider in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 60 | $177,076 |
| RexultiBrexpiprazole | 114 | $165,423 |
| VraylarCariprazine Hcl | 92 | $150,682 |
| PerserisRisperidone | 17 | $48,849 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $42,382 |
| TrintellixVortioxetine Hydrobromide | 42 | $33,960 |
| FanaptIloperidone | 13 | $26,719 |
| Risperidone ErRisperidone Microspheres | 11 | $16,581 |
| Lurasidone Hcl | 49 | $15,903 |
| LinzessLinaclotide | 16 | $9,237 |
| Aripiprazole | 57 | $8,826 |
| Atomoxetine Hcl | 43 | $5,496 |
| Clozapine | 67 | $4,190 |
| Varenicline Tartrate | 16 | $2,427 |
| Oxcarbazepine | 38 | $2,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $678 | $177,07660 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $10,130 | $165,423114 claims |
| AbbVieVraylar, Linzess | $20,267 | $159,919108 claims |
| Indivior Inc.Perseris | $88 | $48,84917 claims |
| Alkermes, Inc.Lybalvi | $295 | $42,38221 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $155 | $33,96042 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $317 | $26,71913 claims |
| Lilly USA, LLCOlanzapine | $227 | $1,032121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Other psychiatric/mental health in Kankakee
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$151K
- Melissa VitaleChicago$151K
- Alan AmbergChicago$119K
- Jaime MendozaMaryville$111K
- Jennifer TheryMaryville$83K
- Carole Weddington HuntGranite City$67K
- Jessica WhelanBloomington$55K
- Julie CarbrayChicago$36K
- Doris van ByssumWheaton$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.